Mr. Spoor has nearly 30 years of executive and management experience in capital markets across the healthcare and medical device industries. Prior to joining Perspective, Mr. Spoor served as president and CEO of KBP Biosciences, where he drove the company’s small molecule clinical development programs. Prior to that, he served as president and CEO of AzurRx BioPharma, where he led its IPO and steered it through multiple clinical trials and regulatory approvals. Before then, he was president and CEO of FluoroPharma Medical, which he took public. Mr. Spoor has also worked as a strategy consultant at Oliver Wyman and as an equity research analyst at JP Morgan and Credit Suisse, where he covered biotechnology stocks and medical device companies. Prior to that, he was at GE Healthcare (Amersham), with increasing commercial leadership roles in the imaging business in cardiology and oncology. Mr. Spoor holds a Pharmacy degree from the University of Toronto and an M.B.A. from Columbia Business School.